Guardant Health Inc (GH) Director Ian T. Clark Sells 81,772 Shares

Guardant Health Inc (NASDAQ:GH) Director Ian T. Clark sold 81,772 shares of the stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $73.90, for a total transaction of $6,042,950.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

GH stock opened at $64.07 on Friday. The company has a market cap of $5.63 billion and a price-to-earnings ratio of -22.88. Guardant Health Inc has a one year low of $27.04 and a one year high of $106.58.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.05. As a group, sell-side analysts predict that Guardant Health Inc will post -1.5 EPS for the current fiscal year.

Several analysts have weighed in on GH shares. JPMorgan Chase & Co. lifted their price objective on shares of Guardant Health from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Friday. Bank of America upgraded shares of Guardant Health from a “neutral” rating to a “buy” rating and set a $84.00 price objective on the stock in a report on Wednesday, April 10th. Cowen upped their target price on shares of Guardant Health from $40.00 to $70.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 3rd. Canaccord Genuity began coverage on shares of Guardant Health in a research report on Tuesday, April 16th. They set a “buy” rating and a $90.00 price target for the company. Finally, Zacks Investment Research lowered shares of Guardant Health from a “hold” rating to a “sell” rating in a research report on Tuesday, April 9th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $83.50.

Large investors have recently added to or reduced their stakes in the stock. Benjamin F. Edwards & Company Inc. purchased a new position in shares of Guardant Health in the fourth quarter worth about $26,000. Mascoma Wealth Management LLC purchased a new position in shares of Guardant Health in the first quarter worth about $54,000. SG Americas Securities LLC purchased a new position in shares of Guardant Health in the first quarter worth about $108,000. Financial Advocates Investment Management purchased a new position in shares of Guardant Health in the fourth quarter worth about $220,000. Finally, Legal & General Group Plc purchased a new position in shares of Guardant Health in the fourth quarter worth about $85,000. Institutional investors and hedge funds own 68.60% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Guardant Health Inc (GH) Director Ian T. Clark Sells 81,772 Shares” was first published by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://www.baseballdailydigest.com/news/2019/05/10/guardant-health-inc-gh-director-ian-t-clark-sells-81772-shares.html.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications.

Recommended Story: Growth and Income Funds

Insider Buying and Selling by Quarter for Guardant Health (NASDAQ:GH)

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.